VISEN Pharmaceuticals (HKG:2561)

Hong Kong · Delayed Price · Currency is HKD

19.04

-0.06 (-0.31%)

Sep 18, 2026, 4:08 PM HKT

Market Cap	2.08B -55.8%
Revenue (ttm)	39.32M -95.1%
Net Income	-276.50M
EPS	-2.55
Shares Out	109.30M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,400
Open	19.10
Previous Close	19.10
Day's Range	18.89 - 19.42
52-Week Range	18.50 - 45.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About VISEN Pharmaceuticals

VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland. The company’s lead product, Lonapegsomatropin, a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. It also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia, that is in phase 2 clinical trial; and Palopegteriparatide, a once-daily parath... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2018

Employees 82

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2561

Full Company Profile

Financial Performance

In 2025, VISEN Pharmaceuticals's revenue was 136,000, a decrease of -95.10% compared to the previous year's 2.78 million. Losses were -253.42 million, 39.1% more than in 2024.

Financial numbers in CNY Financial Statements